|
Real-time Estimate
Cboe BZX
12:00:57 2026-11-18 EST
|
5-day change | 1st Jan Change | ||
| 1.875 USD | -1.32% |
|
-7.39% | -78.76% |
Company Valuation: Atossa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 18.96 | - | - |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -75.12% | - | - |
| Enterprise Value (EV) | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 18.96 | 18.96 | 18.96 |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -75.12% | 0% | 0% |
| P/E | -8.89x | -2.52x | -3.67x | -4.72x | -2.19x | -0.55x | -0.69x | 0.76x |
| PBR | 1.47x | 0.57x | 1.22x | 1.69x | 1.92x | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.3x | -0.1x | 0x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 0.16x |
| EV / Revenue | - | - | - | - | - | - | - | 0.16x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.57x | -0.5x | 0.38x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.7 | -3.15 | -3.6 | -3 | -4.04 | -3.46 | -2.737 | 2.49 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 118.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.52 | -27.69 | -31.38 | -27.62 | -37.14 | -33.21 | -37.99 | 49.52 |
| Net income 1 | -20.61 | -26.96 | -30.09 | -25.5 | -34.77 | -32.47 | -37.99 | 49.52 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 24.000 | 7.927 | 13.200 | 14.161 | 8.850 | 1.900 | 1.900 | 1.900 |
| Nbr of stocks (in thousands) | 8,442 | 8,442 | 8,354 | 8,387 | 8,611 | 9,979 | - | - |
| Announcement Date | 2/28/22 | 3/22/23 | 4/1/24 | 3/25/25 | 3/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.55x | - | - | - | 18.96M | ||
| 17.32x | 6.64x | 12.72x | 1.72% | 66.37B | ||
| 31.83x | 8.5x | 28.08x | 0.07% | 58.86B | ||
| 38.41x | 6.84x | 20.46x | 0.85% | 55.22B | ||
| 44.35x | 6.2x | 29.52x | -.--% | 47.21B | ||
| 33.62x | 3.22x | 13.9x | -.--% | 42.45B | ||
| 35.98x | 8.9x | 23.21x | 0.36% | 36.44B | ||
| -19.28x | 55.7x | -21.11x | -.--% | 35.19B | ||
| 41.59x | 8.02x | 26.91x | -.--% | 32.66B | ||
| -74.36x | 14.09x | -75.73x | -.--% | 26.73B | ||
| Average | 14.89x | 13.12x | 6.44x | 0.33% | 40B | |
| Weighted average by Cap. | 21.61x | 11.64x | 11.39x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATOS Stock
- Valuation Atossa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
















